EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design

Adeniyi T Adewumi, Salerwe Mosebi iD

Biomolecules · 2023

DOI: 10.3390/biom13121798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Adeniyi T Adewumi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life and Consumer Sciences, University of South Africa, Private Bag X06, Florida 1710, South Africa. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) remains the most common cancer among women worldwide, and estrogen receptor-α expression is a critical diagnostic factor for BC. Estrogen receptor (ER-α36) is a dominant-negative effector of ER-α66-mediated estrogen-responsive gene pathways. ER-α36 is a novel target that mediates the non-genomic estrogen signaling pathway. However, the crystallized structure of ER-α36 remains unavailable for molecular studies. ER-positive and triple-negative BC tumors aggressively resist the FDA-approved drugs; therefore, highly potent structure-based inhibitors with preeminent benefits over toxicity will preferably replace the current BC treatment. Broussoflanol B (BFB), a B. papyrifera bark compound, exhibits potent growth inhibitory activity in ER-negative BC cells by inducing cell cycle arrest. For the first time, we unravel the comparative dynamic events of the enzymes’ structures and the binding mechanisms of BFB when bound to the ER-α36 and ER-α66 ligand-binding domain using an all-atom molecular dynamics simulations approach and MM/PBSA-binding-free energy calculations. The dynamic findings have revealed that ER-α36 and ER-α66 LBD undergo timescale “coiling”, opening and closing conformations favoring the high-affinity BFB-bound ER-α36 (ΔG = −52.57 kcal/mol) compared to the BFB-bound ER-α66 (ΔG = −42.41 kcal/mol). Moreover, the unbound (1.260 Å) and bound ER-α36 (1.182 Å) exhibit the highest flexibilities and atomistic motions relative to the ER-α66 systems. The RMSF (Å) of the unbound ER-α36 and ER-α66 exhibit lesser stabilities than the BFB-bound systems, resulting in higher structural flexibilities and atomistic motions than the bound variants. These findings present a model that describes the mechanisms by which the BFB compound induces downregulation-accompanied cell cycle arrest at the Gap0 and Gap1 phases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsFemaleHumansReceptors, EstrogenSignal TransductionEstrogensCell Line, Tumor

Stichwörter der Autor:innen

All-atoms MD simulationsBinding mechanismBreast cancerBroussoflavonol BEstrogen receptor-α36Structure-based inhibitorsTumour Threat

Substanzen

Receptors, EstrogenAntineoplastic AgentsEstrogens

Autor:innen und Institutionen

  • Department of Life and Consumer Sciences, University of South Africa, Private Bag X06, Florida 1710, South Africa.

ORCID-Profile: Salerwe Mosebi

Zitieren

APA

Adewumi, A. T., & Mosebi, S. (2023). Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design. Biomolecules. https://doi.org/10.3390/biom13121798

Vancouver

Adewumi AT, Mosebi S. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design. Biomolecules. 2023. doi:10.3390/biom13121798

BibTeX
@article{Adewumi2023,
  author = {Adewumi, Adeniyi T and Mosebi, Salerwe},
  title = {Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13121798}
}
Kostenlos starten →